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(p = 0.16). Mean dice coefficient for PTV_3D and PTV_4D was 
78%. 
Conclusions:  ITV_4D was larger than GTV_3D which was missed 
on free breathing CT scan and hence compromised PTV_4D 
coverage with 95% isodose. DVH for OAR was not statistically 
different. Tumour delineation on 4D captures tumour motion and 
improves PTV coverage with the prescribed dose. 
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Purpose: The use of Stereotactic Body Radiotherapy (SBRT) in 
patients presenting with oligo-metastatic spine disease has 
increased. However, technical challenges remain due to the 
concave target juxtaposed with the spinal cord. It remains 
unclear if a particular technique allows for superior target 
volume coverage whilst sparing critical structures. We aimed to 
evaluate the dosimetric advantages between three modalities 
for spine SBRT: CyberKnife (CK), Volumetric Modulated Arc 
Therapy (VMAT) and Helical Tomotherapy with Dynamic Jaws 
(HT). 
Methods and Materials: Datasets from 10 consecutive patients 
treated with CK were utilized. Contours were based on the 
International Spine Radiosurgery Consortium Consensus 
Guidelines. All patients were planned to receive 24 Grays (Gy) in 
2 fractions, with the primary goals of: 1) maintaining the max 
tolerance of the cord (≤ 17 Gy) or cauda equine (≤ 20Gy); and 2) 
the clinical target volume (CTV) to receive at least 95% of the 
prescribed dose. During planning priority was given to OAR 
tolerance. Treatment plans were generated by separate 
dosimetrists on the technique-specific software then compared 
using Velocity AI. Parameters of comparison include target 
volume coverage, maximum cord (or cauda) dose, Conformity 
Index (CI), Gradient Index (GI), Homogeneity Index (HI), 
treatment time per fraction (TT) and monitor units (MU) per 
fraction. Statistical analysis was performed with STATA v14. 
Results: CTV mean D98% coverage was significantly worse with 
VMAT (85.7%) versus CK (93.9%) and HT (91.2%, p = 0.01). The 
CTV mean D2% and mean HI were significantly greater in CK 
(129.7%; 41.86) versus VMAT (109.5%; 26.96) and HT (107.6%; 
21.17, p < 0.01 for both). There was no difference in mean CI 
between CK (0.58) and HT (0.60) both were more conformal than 
VMAT (0.42, p < 0.01). Mean GI was sharpest in CK (3.96) versus 
HT (4.86) and VMAT (10.28, p < 0.03). VMAT had the least 
treatment time and MU usage per fraction (8.5 minutes, 9764 
MU) versus HT (27 minutes, 11419 MU) and CK (62.4 minutes, 
14059 MU, p < 0.01). There was no significant difference between 
the three techniques in the maximum dose to the cord or cauda 
equina. 
Conclusions: CK and TOMO plans were both able to achieve 
conformal target coverage while respecting cord tolerance. Dose 
heterogeneity was significantly larger in CK. VMAT required the 
least treatment time and MU, but had the least steep GI, CI and 
target coverage especially for concave shaped targets.  
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Purpose: Thalamic tumours represent 5.2% of all intracranial 
tumours and are typically diagnosed in the paediatric population. 
These tumours arise from glial cells with an aggressive behavior 
and a high grade histology. They have a poor prognosis. The aim 
of this study was to find new approaches for defining the clinical 
target volume for these tumours. 
Methods and Materials: Clinical data was collected form 
archived files of 30 patients diagnosed with thalamic gliomas 
based on pathologic and radiologic criteria. 
Results: Three patterns of tumour spread were found. The first 
pattern followed the thalamic tributaries of the posterior part of 
the internal cerebral veins. These were the anterior and superior 
thalamic veins. For the second pattern the close proximity of the 
internal cerebral vein branches of the superior thalamic veins 
was a potential route of spread between the medial surfaces of 
the thalami. In addition to spread across the midline tumours 
could also spread along the adjacent tectal, pineal and/or 
vermian veins. The third pattern of thalamic tumour spread was 
found in gliomas which use the anterior tributaries of the internal 
cerebral venous architecture of the posterior and inferior 
branches from the basal vein of Rosenthal. 
Conclusions: Thalamic gliomas spread upon the peritumoural 
architecture of the perivenous/subglial Scherer structures and 
this knowledge should be used for redefining the clinical target 
volume for radiation therapy in thalamic gliomas. 
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Purpose: This study was designed to characterize the proportion 
of men who experience hot flashes (flashes), their peak intensity 
and cessation in relation to testosterone (TT) levels, with 
androgen deprivation therapy (ADT). These relationships have 
not been described in the literature previously. We also 
characterize testosterone recovery following 12 months of ADT 
in men undergoing external beam radiation therapy (EBRT) (+/- 
brachytherapy boost).  
Methods and Materials: This is a pre-specified secondary analysis 
of the ASCENDE-RT clinical trial, which is a multicenter, 
randomized trial of dose-escalated EBRT versus low-dose-rate 
brachytherapy for men with unfavourable-risk localized prostate 
cancer. Three hundred and ninety-eight men were randomized. 
All received 12 months of ADT with luteinizing hormone releasing 
hormone (LHRH) agonist plus a non-steroidal anti-androgen for 
at least one month. TT was measured every two months until 
eight months, at one year, every three months until 24 months, 
every six months until five years, and yearly thereafter. Patients 
were censored at last follow up or at date of PSA failure. TT 
recovery was defined as any single serum TT above threshold, as 
defined below. Presence and intensity of flashes were assessed 
every four months until one year, every six months until five 
years, and yearly thereafter. 
Results: TT and hot flash data were available in 392 patients. 
Analysis was restricted to 334 patients in which baseline (pre-
ADT) TT was collected. Median age at first LHRH injection was 
68 years (range 45-86). Median follow up from date of ADT to last 
assessment of flashes was 6.1 years. Median TT at baseline was 
13.1 nmol/L. All patients with baseline TT ≥ 5 (91% of study 
cohort) recovered TT to this threshold with a median time to 
recovery of 9.6 months. Eighty-seven percent of patients with 
baseline TT ≥ 7.5 (84% of study cohort) recovered TT to this 
threshold after a median of 12.7 months. Eighty-one percent of 
patients with baseline TT ≥ 10 (68% of study cohort) recovered 
TT to this threshold after a median time of 18.2 months. Ninety-
four percent of men experienced flashes at some point. Flashes 
were first reported at a median of 4.0 months from first LHRH 
injection, when the TT had fallen to castrate. Peak intensity of 
flashes also occurred at this time and TT level. Median time of 
cessation of flashes was 7.6 months following cessation of ADT, 
when median TT had risen to 5.7 nmol/L. Ninety-one percent of 
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patients recover TT to at least this level within a median 10.9 
months. At last follow up, 99.7% of men had cessation of flashes. 
Conclusions: Hot flashes occur with castrate levels of 
testosterone, and cease when TT has recovered to about half the 
pre-intervention level (5.7nmol/L). Over 90% recover to at least 
this level. 
